Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Luye Pharma GroupFRA:LUP +5.17%52 ROC (Joel Greenblatt) % is 19.57% as of Dec. 2025, which is 11% below its 10-year median of 22.00. GuruFocus rates FRA:LUP with a GF Score™ of 52/100 and a GF Value™ of €0.35 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 983 Drug Manufacturers companies, Luye Pharma Group ranks better than 63.78% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Luye Pharma Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 19.57%.
The historical rank and industry rank for Luye Pharma Group's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:LUP'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 5.08 Med: 22 Max: 45.03
Current: 19.99
During the past 13 years, Luye Pharma Group's highest ROC (Joel Greenblatt) % was 45.03%. The lowest was 5.08%. And the median was 22.00%.
FRA:LUP's ROC (Joel Greenblatt) % is ranked better than 63.78% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs FRA:LUP: 19.99
Luye Pharma Group's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 12.00% per year.
Luye Pharma Group (FRA:LUP) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Luye Pharma Group ROC (Joel Greenblatt) % Related Terms
Luye Pharma Group ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LUP vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's ROC (Joel Greenblatt) % falls into.
Luye Pharma Group ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 19.57% mean?
Luye Pharma Group (FRA:LUP) has a ROC (Joel Greenblatt) % of 19.57% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Luye Pharma Group and its competitors. This is 11% below median its historical median of 22.00. Over the past decade, Luye Pharma Group's ROC (Joel Greenblatt) % has ranged from 5.08 to 45.03. According to the industry distribution chart, Luye Pharma Group ranks #356 out of 983 companies in the Drug Manufacturers industry, placing it in the top 36.2%.
Is Luye Pharma Group's ROC (Joel Greenblatt) % too high?
Luye Pharma Group's current ROC (Joel Greenblatt) % of 19.57% is 11% below median its 10-year median of 22.00. Over the past 10 years, this metric has ranged from a low of 5.08 to a high of 45.03. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. Luye Pharma Group's value of 19.57% is 70.8% above this industry median. Based on the distribution chart, Luye Pharma Group ranks #356 out of 983 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Luye Pharma Group has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #356 out of 983 companies for ROC (Joel Greenblatt) %. This puts Luye Pharma Group in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. Luye Pharma Group's value of 19.57% is 70.8% above this benchmark. Historically, Luye Pharma Group's own ROC (Joel Greenblatt) % has ranged from 5.08 to 45.03 over the past decade. While the company's 10-year median is 22.00 vs. the industry median of 11.46, Luye Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current ROC (Joel Greenblatt) % of 19.57% is 70.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Luye Pharma Group and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current ROC (Joel Greenblatt) % is 19.57%, which is 11% below median its own 10-year median of 22.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.35, compared to a current price of €0.24 — trading 30.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 19.57%, which is 11% below median its 10-year median of 22.00 and 70.8% above the Drug Manufacturers industry median of 11.46. Luye Pharma Group's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current ROC (Joel Greenblatt) % is 19.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.24 is trading 30.3% below its estimated GF Value™ of €0.35.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
ROC (Joel Greenblatt) %: 19.57% (11% below median its 10-year median of 22.00)
GF Value™: €0.35 vs. price of €0.24 (30.3% below fair value)
Industry Position: 70.8% above the Drug Manufacturers median (#356 of 983)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
52GF Score
Get the complete analysis for FRA:LUP
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
